Johnson & Johnson (JNJ) Reports 100% Success in OMNY-AF Study

Johnson & Johnson (NYSE:JNJ) is among the most profitable mega cap stocks to buy. On February 6, Johnson & Johnson (NYSE:JNJ) disclosed 12-month pilot-phase data from the OMNY-AF study, which examined the investigational OMNYPULSE Platform for the treatment of symptomatic paroxysmal atrial fibrillation (AFib). Announced during the 31st Annual AF Symposium in Boston, the results reveal that investigators achieved 100% acute procedural success with zero adverse events linked to the procedure.

As stated by Dinesh Sharma, M.D., Section Head of Cardiac Electrophysiology at the Naples Heart Institute,

“The 12-month data provide encouraging early evidence on the OMNY-AF study with promising safety outcomes – no procedure-related adverse events or MRI-detected cerebral lesions – across eight centers in the pilot phase.”

Earlier on February 3, RBC Capital increased the price target on Johnson & Johnson (NYSE:JNJ) to $255 from $240 and reiterated an Outperform rating following investor questions about the Daubert decision related to talc litigation and how it will impact the company financially.

According to the firm’s analysis, Johnson & Johnson (NYSE:JNJ) is unlikely to overturn the key consequences of the Daubert ruling, but the case may continue for years. Despite this, the firm remains confident in the healthcare giant’s financial position, given its strong performance, which helps reduce risk.

Johnson & Johnson (NYSE:JNJ) is a global healthcare company focused on innovative medicines and medical technologies. Headquartered in New Jersey, the company serves a wide clientele, including retailers, wholesalers, healthcare professionals, and hospitals.

While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.